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Abstract: Review on MIR133B, with data on DNA/RNA, on the protein encoded and where the gene is 
implicated. 
 
Identity 
Other names: MIRN133B, miRNA133B, mir-133b 
HGNC (Hugo): MIR133B 
Location: 6p12.2 
Local order: Based on MapViewer, gene flanking 
MIR133B oriented from centromere to telomere on 
6p12.2 are:  
- MCM3: minichromosome maintenance complex 
component 3  
- IL17F: interleukin 17F  
- IL17A: interleukin 17A  
- MIR133B: microRNA 133B  
- MIR206: microRNA 206  
- PKHD1: polycystic kidney and hepatic disease 1 
(autosomal recessive). 
DNA/RNA 
Description 
Homologues have been discovered in several other 
species including invertebrates, most of which has 
multiple miR133 family members. For example, the 
human genome encodes three miR133 genes: 
miR133A1, miR133A2 and miR133B on chromosomes 
18, 20 and 6, respectively. 
Transcription 
MiR133B is specifically modestly expressed in the 
substantia nigra pars compacta as well as in 
GABAergic neurons of cortex and cerebellum. The 
beginning and the end of the pri-miR133B sequence are 
unknown. 
Pre-miR133B 
miRBase accession number: MI0000822. 
Length: 119 nucleotides. 
Sequence: 
5'-
CCTCAGAAGAAAGATGCCCCCTGCTCTGGCTG
GTCAAACGGAACCAAGTCCGTCTTCCTGAGAG
GTTTGGTCCCCTTCAACCAGCTACAGCAGGGCT
GGCAATGCCCAGTCCTTGGAGA-3' 
Mature miR133B 
miRBase accession number: MIMAT0000770. 
Length: 22 nucleotides. 
Sequence: 
5'-TTTGGTCCCCTTCAACCAGCTA-3' 
Pseudogene 
Pseudogenes were not reported. 
Protein 
Note 
MicroRNAs are not translated into aminoacids. 
Mutations 
Note 
A single nucleotide variation was reported (Reference 
SNP ID: rs112599381). The variation is T>C at 
position 52013754 (according to hg19-Feb_2009) with 
unknown frequency. 
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A. Homo sapiens stem-loop structure of pre-miR133B. Red characters indicate mature miR133B sequence. B. The human miR133 family 
members. 
 
Implicated in 
Bladder cancer 
Note 
A subset of 7 miRNAs (miR-145, miR-30a-3p, miR-
133a, miR-133b, miR-195, miR-125b and miR-199a*) 
were found to be significantly downregulated in 
bladder cancers (Ichimi et al., 2009). 
Prognosis 
Dyrskjøt et al. identified several miRNAs with 
prognostic potential for predicting bladder tumor 
progression (e.g., miR-129, miR-133b, and miR-518c*) 
(Dyrskjøt et al., 2009).  
miR-133a and miR-133b were found to inhibit cell 
proliferation, migration and invasion in T24 and EJ 
cells.  
The first evidence was provided that miR-133a and 
miR-133b may directly target the epidermal growth 
factor receptor in bladder cancer (Zhou et al., 2012). 
Cervical carcinoma 
Note 
Transfection with miR-133b rendered HeLa cells 
sensitive to TNF-a, TRAIL and FasL-induced cell 
death, by targeting the antiapoptotic protein Fas 
apoptosis inhibitory molecule (FAIM) (Patron et al., 
2012). 
Oncogenesis 
miR-133b enhances cell proliferation and colony 
formation by targeting mammalian sterile 20-like 
kinase 2 (MST2), cell division control protein 42 
homolog (CDC42) and ras homolog gene family 
member A (RHOA), which subsequently results in 
activation of the tumorigenic protein kinase B alpha 
(AKT1) and mitogen-activated protein kinase (ERK1 
and ERK2, here abbreviated as ERK) signaling 
pathways.  
Upregulation of miR-133b in cervical carcinoma cells 
strongly promotes both in vivo tumorigenesis and 
independent metastasis to the mouse lung (Qin et al., 
2012). 
Colorectal cancer 
Note 
Downregulation of miR-133b expression was 
significant in human colorectal cancer tissues compared 
with adjacent normal tissues.  
Ectopic expression of miR-133b potently affected 
colorectal cancer cell proliferation and apoptosis in 
vitro and in vivo by direct targeting of the receptor 
tyrosine kinase MET (Hu et al., 2010). Overexpression 
of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, 
HS287, miR-28-5p, miR-143, miR-199b-5p, miR-
199a-5p, miR-10b, miR-22, miR-133b, miR-145*, 
miR-199a, miR-133a, miR-125b and downregulation of 
miR-31 and HS170 were observed in brain-metastatic 
colorectal carcinomas (Li et al., 2012). 
Prognosis 
High expression of miR-185 and low expression of 
miR-133b were correlated with poor survival (p=0.001 
and 0.028, respectively) and metastasis (p=0.007 and 
0.036, respectively) in colorectal cancer. (Akçakaya et 
al., 2011). 
Gastric cancer 
Note 
The most highly expressed miRNAs in non-tumorous 
tissues were miR-133b as well as miR-768-3p, miR-
139-5p, miR-378, miR-31, miR-195, miR-497, 
compared to in gastric cancer tissues (Guo et al., 2009).  
miR-133b was downregulated in high-grade 
gastrointestinal stromal tumors. Fascin-1 mRNA was 
upregulated in accordance with miR-133b 
downregulation in high-grade gastrointestinal stromal 
tumors; this result was consistent with a previous report 
showing that fascin-1 might be a direct target of miR-
133b (Yamamoto et al., 2013). miR-133b targets 
FGFR1 and inhibits gastric cancer cell growth (Wen et 
al., 2013). 
Lung cancer 
Prognosis 
MiR-133B had the lowest expression of miRNA in 
lung tumor tissue compared to adjacent uninvolved 
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tissue. Selective over-expression of miR-133B in 
adenocarcinoma (H2009) cell lines resulted in reduced 
expression of MCL-1 and BCL2L2. MiR-133B directly 
targets the 3'UTRs of both MCL-1 and BCL2L2. 
Lastly, over-expression of miR-133B induced apoptosis 
following gemcitabine exposure in these tumor cells 
(Crawford et al., 2009). miR-133b can inhibit cell 
growth of NSCLC through targeting EGFR and 
regulating its downstream signaling pathway (Liu et al., 
2012). 
Oncogenesis 
Serum miR-206 and miR-133b were significantly up-
regulated in the early stage of 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone-induced lung carcinogenesis. 
miR-206 and miR-133b exhibited low-expression in 
lung cancer tissues (Wu et al., 2013). 
Osteosarcoma 
Note 
A set of miRNAs, miR-1, miR-18a, miR-18b, miR-19b, 
miR-31, miR-126, miR-142-3p, miR-133b, miR-144, 
miR-195, miR-223, miR-451 and miR-497 was 
identified with an intermediate expression level in 
osteosarcoma clinical samples compared to osteoblasts 
and bone (Namløs et al., 2012). 
Prostate cancer 
Note 
miR-133a and miR-133b are expressed at the detection 
limit in two hormone-insensitive prostate cancer cell 
lines, PC3 and DU145. Ectopic expression of miR-133 
inhibited cell proliferation, migration and invasion in 
these cells, possibly by targeting EGFR (Tao et al., 
2012). A significant lower expression of miR-1, miR-
133b and miR-378* was observed in osteosarcomas 
with respect to control, and also in 31 high-grade 
osteosarcomas than in 25 low-grade and in metastatic 
versus non-metastatic patients. The expression of miR-
1 and miR-133b may control cell proliferation and cell 
cycle through MET protein expression modulation 
(Novello et al., 2013). 
Oncogenesis 
miR-133b is directly up-regulated by androgen 
receptor, represses CDC2L5, PTPRK, RB1CC1, and 
CPNE3, and, is essential to prostate cancer cell survival 
(Mo et al., 2013). 
Squamous cell carcinoma 
Note 
MiR133B expression was downregulated in laser 
microdissected cells of tongue squamous cell 
carcinoma (Wong et al., 2008b). MiR-133b as well as 
miR-145, miR-30a-3p, and miR-133a are 
downregulated in esophageal squamous cell carcinoma 
(Kano et al., 2010). 
Oncogenesis 
Tongue squamous cell carcinoma cell lines transfected 
with miR133a and miR-133b precursors displayed 
reduction in proliferation rate possibly through the 
downregulation of pyruvate kinase type M2 (Wong et 
al., 2008a). Gain-of-function analysis revealed that 3 
transfectants (miR-145, miR-133a and miR-133b) 
inhibit cell proliferation and cell invasion in esophageal 
squamous cell carcinoma cells (Kano et al., 2010). 
miR-133b, was downregulated in esophageal squamous 
cell carcinoma tissue compared with the adjacent 
normal tissue. Bioinformatics analyses identified that 
miR-133b was found to be involved in invasion and 
metastasis of esophageal squamous cell carcinoma (Fu 
et al., 2013). 
Muscular development 
Note 
miR-133b as well as miR-1, miR-133a, and miR-206 
levels were found increased during late stages of 
human foetal muscle development. Increases in the 
expression levels of these miRNAs were proportional 
to the capacity of myoblasts to form myotubes. 
Changes in miRNA levels during human foetal 
development were accompanied by endogenous 
alterations in their known targets and also in their 
inducer, MyoD. Ectopic MyoD expression caused an 
induction of muscle cell differentiation in vitro, 
accompanied by an increase in the levels of miR-1, 
miR-133a, miR-133b and miR-206 (Koutsoulidou et 
al., 2011). 
Myocardial hypertrophy and heart 
failure. 
Note 
MiR133B expression was downregulated in the heart 
obtained from idiopathic cardiomyopathy and ischemic 
patients (Sucharov et al., 2008). 
Disease 
Down-regulation of miR-133b induced an increase in 
cardiomyocyte size while over-expression of miR-133b 
dramatically reduced the cell size, suggesting that miR-
133b may be a global regulator of cardiomyocyte 
hypertrophy (Sucharov et al., 2008).  
Xiao et al. quantified the muscle-specific microRNA 
subtypes miR-133a and miR-133b, which can 
posttranscriptionally regulate and repress KvLQT1 
protein expression without affecting mRNA expression 
(Xiao L et al., 2008). miR-1, miR-133a, miR-133b, and 
miR-208b were independently associated with high-
sensitivity troponin T levels (all P<0.001) in plasma 
samples obtained on admission from 444 patients with 
acute coronary syndrome (Widera et al., 2011). 
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